RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Clinical trials for RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine combo shows promise in ovarian cancer fight
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own white blood cells, combined with an immunotherapy drug (pembrolizumab), for people with ovarian cancer that has returned. The vaccine targets a protein found on many ovarian cancer cells, training the immune system…
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 02:15 UTC
-
New drug combo targets Hard-to-Treat ovarian and endometrial cancers
Disease control Recruiting nowThis early-phase study tests a combination of two experimental drugs (M1774 and ZEN-3694) in people whose ovarian or endometrial cancer has returned after previous treatment. The goal is to find the safest dose and see how well the drugs work together to stop cancer cell growth. …
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
New hope for recurrent ovarian cancer: triple drug attack launched
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to two standard immunotherapies (pembrolizumab and bevacizumab) can shrink tumors in people whose ovarian cancer has returned. About 80 adults with specific types of recurrent ovarian, fallopian tube, or peritoneal c…
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 11, 2026 20:50 UTC